FDA moves toward easing restrictions on certain peptides BioPharma Dive In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for BPC 157 free base CAS#137525 51 0 cytoprotective agent Restoring Balance: What the FDA's Peptide Announcement Could Mean for Patient Access and Safety Empower Pharmacy